SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

Cytovia Therapeutics Highlights Presentation Of CYT-338 Data At European Hematology Association Annual Congress

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical

Benzinga · 06/10/2022 08:05

Data supports further development of CYT-338 in relapsed/refractory multiple myeloma

AVENTURA, Fla. and NATICK, Mass., June 10, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.

Cytovia Therapeutics (PRNewsfoto/Cytovia Therapeutics)

For details on in-person poster presentations, please see the following:

Title: NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS

Session Title: Poster session

Session date and time: Friday, June 10 2022 - 16:30 - 17:45 CEST

Final Abstract Code:  P842


Abstract Link:  https://library.ehaweb.org/eha/2022/eha2022-congress/357704/antonio.arulanandam.novel.multifunctional.tetravalent.cd38.nkp46.flex-nk.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DNK